In this systematic review and meta-analysis, moderate quality of evidence shows that SGLT-2 inhibitors administered to patients with CKD with or without T2DM reduce the risk of the primary cardiovascular and renal outcomes, as well as the hazard for all-cause mortality, CV death and hospitalization for HF outcomes. Here, SLC5A2 is linked to chronic kidney disease.